Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19375656 | 0.86 | GLP1R (0.44) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL22096266 | 0.85 | GLP1R (0.46) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL17531842 | 0.85 | GLP1R (0.44) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL25585043 | 0.85 | GLP1R (0.46) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL19375717 | 0.84 | GLP1R (0.43) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL25579755 | 0.84 | GLP1R (0.43) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL19375648 | 0.82 | GLP1R (0.49) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL19375755 | 0.82 | GLP1R (0.49) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL19375657 | 0.81 | TSHR (0.36) | GLP1RTSHRNPC1LMNARAB9A | |
| SCHEMBL13699548 | 0.81 | GLP1R (0.46) | GLP1RTSHRNAMPTEPHX2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | CD4, MET, TNFSF10 | GLP1R 4649/4885TSHR 2160/4885NPC1 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.